Komori
Treasury Shares4547KISSEI PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Notice Regarding the Results of the Acquisition of Treasury Shares through an Off-Auction Purchase (ToSTNeT-3)

On 5 November, the company acquired 1,032,500 treasury shares through ToSTNeT-3, an off-auction trading system. Cumulative acquisitions since 12 May 2026 reached 1,232,500 shares, with an acquisition cost of ¥4,676,349,000.

Worth reading
73In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
3877037500
¥
Wording
Definitive
How definitive the wording is.

Progress against acquisition limit

Purchase through the Tokyo Stock Exchange's off-auction purchase transaction for treasury shares (ToSTNeT-3)

Resolved 11 May 2026 and 4 November 2026 / Acquisition period 5 November 2026 / 12 May 2026 to 31 December 2026

—
No Track Record Reported
Limit
Number of Shares1,100,000 shares (maximum) / 1,300,000 shares (maximum)
—
No Track Record Reported
Limit
Amount¥4,130,500,000 (maximum) / ¥6,000,000,000 (maximum)

The darker band is the portion acquired this time (5 November 2026).

Number of Shares
Limit1,100,000 shares (maximum) / 1,300,000 shares (maximum)
Cumulative total1,232,500 shares (12 May 2026 to 5 November 2026)
Current1,032,500 shares
Amount
Limit¥4,130,500,000 (maximum) / ¥6,000,000,000 (maximum)
Cumulative total¥4,676,349,000 (12 May 2026 to 5 November 2026)
Current¥3,877,037,500
Percentage of total issued shares2.64%/3.14%
Average acquisition price for this transaction (calculated)¥3,755 per shareCurrent acquisition price ÷ current number of shares acquired

ToSTNeT is a system for trading outside the exchange's regular trading hours.

Progress against acquisition limit
ItemDetails
Total number of shares acquired in this transaction1,032,500 shares
Total current acquisition price¥3,877,037,500
Acquisition date/acquisition period5 November 2026
Method of acquisitionPurchase through the Tokyo Stock Exchange's off-auction purchase transaction for treasury shares (ToSTNeT-3)
Cumulative number of shares acquired1,232,500 shares (12 May 2026 to 5 November 2026)
Cumulative acquisition cost¥4,676,349,000 (12 May 2026 to 5 November 2026)
Resolution date11 May 2026 and 4 November 2026
Maximum number of shares to be acquired1,100,000 shares (maximum) / 1,300,000 shares (maximum)
Total acquisition price¥4,130,500,000 (maximum) / ¥6,000,000,000 (maximum)
Acquisition period under the resolution5 November 2026 / 12 May 2026 to 31 December 2026
Percentage of total issued shares2.64%/3.14%
Items this document does not state (2)
Whether acquisition has been completedAverage Acquisition Price

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To implement a flexible capital policy in response to changes in the business environment, improve capital efficiency, and enhance shareholder returns.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Results of the Acquisition of Treasury Shares through an Off-Auction Purchase (ToSTNeT-3) | KISSEI PHARMACEUTICAL CO.,LTD. (4547) timely disclosure | Komori